Resistant gastroenteropancreatic neuroendocrine tumors: a definition and guideline to medical and surgical management.

Autor:	Davis CH; Division of Surgical Oncology, Baylor University Medical Center, Dallas, Texas, USA.; Texas A&M University School of Medicine, Dallas, Texas, USA., Laird AM; Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.; Rutgers Robert Wood Johnson University Medical School, New Brunswick, New Jersey, USA., Libutti SK; Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.; Rutgers Robert Wood Johnson University Medical School, New Brunswick, New Jersey, USA.
Jazyk:	angličtina
Zdroj:	Proceedings (Baylor University. Medical Center) [Proc (Bayl Univ Med Cent)] 2023 Dec 20; Vol. 37 (1), pp. 104-110. Date of Electronic Publication: 2023 Dec 20 (Print Publication: 2024).
DOI:	10.1080/08998280.2023.2284039
Abstrakt:	Gastroenteropancreatic neuroendocrine tumors (NETs), also historically known as carcinoids, are tumors derived of hormone-secreting enteroendocrine cells. Carcinoids may be found in the esophagus, stomach, small intestine, appendix, colon, rectum, or pancreas. The biologic behavior of carcinoids differs based on their location, with gastric and appendiceal NETs among the least aggressive and small intestinal and pancreatic NETs among the most aggressive. Ultimately, however, biologic behavior is most heavily influenced by tumor grade. The incidence of NETs has increased by 6.4 times over the past 40 years. Surgery remains the mainstay for management of most carcinoids. Medical management, however, is a useful adjunct and/or definitive therapy in patients with symptomatic functional carcinoids, in patients with unresectable or incompletely resected carcinoids, in some cases of recurrent carcinoid, and in postoperative patients to prevent recurrence. Functional tumors with persistent symptoms or progressive metastatic carcinoids despite therapy are called "resistant" tumors. In patients with unresectable disease and/or carcinoid syndrome, an array of medical therapies is available, mainly including somatostatin analogues, molecular-targeted therapy, and peptide receptor radionuclide therapy. Active research is ongoing to identify additional targeted therapies for patients with resistant carcinoids. Competing Interests: The authors report no funding or conflicts of interest. (Copyright © 2023 Baylor University Medical Center.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu